Sources — Global Fund OIG research
Every quantitative or status claim in The award was signed. The proof was not ready. maps to a primary OIG locator below. Primaries read 22 Sep 2026 (Africa/Cairo).
Primary PDFs
| ID | Title (short) | Date | Type | URL |
|---|---|---|---|---|
| GF-OIG-25-005 | Global Fund Grants to the Togolese Republic | 4 Jun 2025 | Audit | https://www.theglobalfund.org/media/gbqltprg/oig_gf-oig-25-005_report_en.pdf |
| GF-OIG-26-008 | Ghana — Fraudulent Practice in Proposing for Consultancy Services | 15 Jun 2026 | Investigation | https://www.theglobalfund.org/media/r22gmylm/oig_gf-oig-26-008_report_en.pdf |
| GF-OIG-23-022 | Global Fund Grants in Zambia (granular chlorine) | 20 Dec 2023 | Investigation | https://www.theglobalfund.org/media/drtkbofz/oig_gf-oig-23-022_report_en.pdf |
| GF-OIG-26-006 | Fraudulent Practices in the Sale of Rapid Diagnostic Tests | 9 Jun 2026 | Investigation | https://www.theglobalfund.org/media/ehkfvxio/oig_gf-oig-26-006_report_en.pdf |
Index: https://www.theglobalfund.org/en/oig/reports/
GF-OIG-26-013 (Secretariat indirect procurement) was screened and not used as a fourth case; weaker award-file narrative fit.
Claim → locator table
Framing / method (not OIG facts)
| Claim | Locator |
|---|---|
| Public OIG only; not Trace-li clients; no “would have prevented” | Note method — labelled as such |
| Cost-of-proof voice; a cheap unfinished tool vs finished-work frame | Trace-li Research Desk framing — labelled as such |
| Product wireframes illustrative | Captions in the note; illustrative product UI |
Togo — GF-OIG-25-005
| Claim ID | Statement | Locator | Qualification |
|---|---|---|---|
| T-01 | Report GF-OIG-25-005; audit of GF grants in Togo; 4 Jun 2025 | PDF cover / header | Distinct from GF-OIG-26-004 |
| T-02 | PR = Office of the Prime Minister (HIV, TB, malaria) | Background / portfolio section | — |
| T-03 | Procurement & financial management controls: Partially Effective | Exec. Summary / rating table (~pp. on “Partially Effective”) | Audit opinion |
| T-04 | Non-health €2.4m (GC5) → €7.9m (GC6), excl. C19RM | §4.4 p. 18; fn 60 | — |
| T-05 | Additional estimated €29m C19RM non-health budgeted in GC6 | §4.4 p. 18; fn 61 | Estimated / budgeted |
| T-06 | GC7 projected €5.4m (~5% of grants’ budget) | §4.4 p. 18; fn 62 | Projection |
| T-07 | OIG reviewed 30 contracts = 64% of non-health value 2021–2023 | §4.4 p. 18; fn 63 | Sample |
| T-08 | Of €10m reviewed, incomplete files for €2.7m | §4.4 p. 19 | Incomplete ≠ diversion |
| T-09 | 3 contracts restricted negotiation or single source despite rules; GF non-objection | §4.4 p. 19 | Non-objection ≠ clean bill |
| T-10 | Extensions: 30% up to 18 months; authorisation/documentation gaps | §4.4 p. 19 | — |
| T-11 | CT scanners contract €2m (2023); unfulfilled as of Oct 2024 | §4.4 p. 18 | Status as of Oct 2024 per OIG |
| T-12 | AMA 3: assess PMU procurement capacity; due 30 Jun 2026 | AMA 3 (~p. 20) | Agreed ≠ implemented |
| T-13 | Delayed DHIS2 phones / LLIN devices examples | §4.4 p. 18 | Programmatic examples |
| T-14 | ~49% GC6 funds on health products via PPM | §4.4 p. 18 | Framing in finding |
| — | Funds diverted from €2.7m incomplete subset | — | NOT SUPPORTED — do not claim |
Ghana — GF-OIG-26-008
| Claim ID | Statement | Locator | Qualification |
|---|---|---|---|
| G-01 | Investigation of services contract valued at US$831,440 | §1.1 Investigation at a glance (p. 4) | — |
| G-02 | Fraudulent practices in proposing / negotiations re labour-cost components | §1.1; §2.1 | Code of Conduct (2021); administrative |
| G-03 | Single-sourced DPMU; initial US$361,364 effective 5 Oct 2021; raised to US$831,440 | §1.2 Genesis and scope | — |
| G-04 | Impact ≈ US$240,208 on contract value | §1.5 Impact; §2.1 title/body (p. 7) | OIG estimate |
| G-05 | No national-law determination | §1.1 / Annex B methodology language | Investigation ≠ criminal |
| G-06 | Secretariat AMA via Sanctions Panel Procedures; Procurement Manual AMA | §3 Global Fund Response (pp. 12–13) | Marked Implemented in table |
Zambia — GF-OIG-23-022
| Claim ID | Statement | Locator | Qualification |
|---|---|---|---|
| Z-01 | Collusion on granular chlorine for COVID preparedness | §1.1 (p. 3) | — |
| Z-02 | Three local suppliers; steered to Supplier 1 with PR-employee links | §1.1 | — |
| Z-03 | Contract US$78,030 non-compliant | §1.1; Impact section | Full contract non-compliant |
| Z-04 | Overpay US$33,092 potentially recoverable | §1.1; Impact (recommends recovery) | Potentially recoverable ≠ recovered |
| Z-05 | Goods delivered; scheme narrow | Impact narrative | — |
| Z-06 | AMA to recover + actions on individuals/suppliers; LFA >US$50k; ZAMMSA shift | Impact / mitigating measures | AMA agreed ≠ completed |
| Z-07 | Grant reference ZMB-C-MOH | §1.1 | — |
RDT sales — GF-OIG-26-006
| Claim ID | Statement | Locator | Qualification |
|---|---|---|---|
| R-01 | Fraudulent practices in sale of HIV/malaria RDTs (direct or via PSA) | §1.1 (pp. 4–5) | Preponderance / more likely than not |
| R-02 | Stopped sourcing uncut sheets from WHO-stated manufacturer; no required notification | §1.1 | — |
| R-03 | 28 countries; 34.4m RDTs; approx. US$12.3m | §1.2 / page 5 text + fn 9 | Approximate value |
| R-04 | ~89% (30.8m) could not have contained WHO-stated strips | Impact §1.4 (p. 6–7) | OIG calculation |
| R-05 | ~US$11m approx. value of potentially non-compliant RDTs (7.1m HIV + 23.7m malaria est.) | §2.1 (≈p. on “approximately US$11 million”) | Approximate; scale illustration |
| R-06 | ~3.4% of ~1bn GF-funded HIV/malaria RDTs in period | §1.4 | Context |
| R-07 | No efficacy / adverse-outcome findings | §1.1; §1.2 | Hard qualification |
| R-08 | Non-compliance with OIG information/access requests | Finding 2 / §2.2 | — |
| R-09 | Secretariat AMA via Sanctions Panel Procedures | §1.4 Impact; §3 Response | — |
Cross-pack / charts
| Chart | Data used | Sources |
|---|---|---|
charts/01-togo-nonhealth-volume.png | €2.4 / €7.9 / est. €29 / €5.4 | T-04, T-05, T-06 |
charts/02-togo-incomplete-files.png | €2.7 of €10 | T-08 |
charts/03-cross-case-money.png | €2.7m; ~US$240k; US$33k; ~US$11m | T-08, G-04, Z-04, R-05 |
charts/04-pattern-matrix.png | Qualitative synthesis | All four primaries — labelled synthesis |
charts/05-ghana-contract-impact.png | US$831,440 / ~US$240,208 | G-01, G-04 |
charts/06-value-chain-map.png | Stages Intake→Freeze + gap-type synthesis | All four primaries — labelled synthesis; product path illustrative |
Dropped / not used
| Item | Reason |
|---|---|
| GF-OIG-24-014 Cameroon | Prefer inventory-heavy; weaker award-file fit vs RDT |
| GF-OIG-26-013 Indirect Procurement | Secretariat process audit; 21%/49% sample stats are useful but not a country award-file story; retained PDF only |
| GF-OIG-26-004 | Explicitly out of scope for Togo pack; do not merge with 25-005 |
| Any “Trace prevented X” counterfactual | Hard pack rule |
| Recovery-as-completed language | Reports say recommended / potentially recoverable / AMA |
| RDT efficacy or patient-harm claims | Explicitly not supported by OIG |